Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 20, 2020 16:01 ET | Source: Forty Seven, Inc.

Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

-- Presented Updated Data for Magrolimab Showing Robust, Durable Activity in MDS and AML ---- Presented Foundational Preclinical Data for FSI-174 and Entered into Collaborations with bluebird bio and...
March 11, 2020 08:00 ET | Source: Forty Seven, Inc.

Forty Seven and Rocket Pharmaceuticals Announce Research Collaboration for Fanconi Anemia

MENLO PARK, Calif. and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV) and Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) announced today that they have entered into a...
February 25, 2020 08:00 ET | Source: Forty Seven, Inc.

Forty Seven to Present at Upcoming Investor Conferences in March

MENLO PARK, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...
February 06, 2020 08:00 ET | Source: Forty Seven, Inc.

Forty Seven to Present at Upcoming Investor Conferences in February

MENLO PARK, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...
January 10, 2020 08:00 ET | Source: Forty Seven, Inc.

Forty Seven Announces 2020 Strategic Priorities and Expected Milestones

-- Registration-Enabling Programs in MDS and DLBCL On-Track; Initiation of Phase 3 ENHANCE Trial in MDS and Phase 3 Trial in DLBCL Expected in 1Q and 2Q 2020 -- -- Updated Data from Ongoing Phase 1b...
December 16, 2019 16:01 ET | Source: Forty Seven, Inc.

Forty Seven, Inc. Announces Closing of Underwritten Public Offering and Exercise in Full of Option to Purchase Additional Shares

MENLO PARK, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the closing of its previously announced public...
December 11, 2019 22:32 ET | Source: Forty Seven, Inc.

Forty Seven, Inc. Prices Underwritten Public Offering of 4,860,000 Shares of Common Stock

MENLO PARK, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the pricing of its previously announced underwritten...
December 11, 2019 16:01 ET | Source: Forty Seven, Inc.

Forty Seven, Inc. Announces Proposed Underwritten Public Offering of Common Stock

MENLO PARK, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced that it has commenced an underwritten public...
December 09, 2019 10:00 ET | Source: Forty Seven, Inc.

Forty Seven, Inc. Announces Foundational Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation

-- Expect to Initiate Phase 1 Clinical Trial in Healthy Volunteers in First Quarter of 2020 ---- Forty Seven to Host Investor Event and Webcast at 8:00 p.m. ET -- MENLO PARK, Calif., Dec. 09, 2019...
December 09, 2019 07:00 ET | Source: Forty Seven, Inc.

Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

-- CR Rate of 50% and ORR of 92% Observed in Untreated Patients with Higher-Risk MDS ---- CR/CRi Rate of 55% and ORR of 64% Observed in Patients with Untreated AML Who are Ineligible for Induction...